PerkinElmer (PE) signed two-year research collaboration agreements with Johns Hopkins University (JHU) and the University of Birmingham, U . K ., to establish the groundwork for developing tools and technologies for discovery of biomarkers leading to diagnostics and personalized medicine.

Mary Lopez, Ph.D., strategic collaborations leader, PE, said that the collaborations are “purely for research into biomarker discovery in cancer. PE’s collaboration with Dr. Daniel Chan at JHU and Dr. Philip Johnson at the University of Birmingham expands their ongoing research into lung, liver, and ovarian cancers by giving them tools and expertise.

“The researchers will be making use of PE’s BioExpression platform with its carrier protein-based biomarker enrichment technology, and PE would be interested in licensing any biomarkers discovered as a result of the research collaboration,” Dr. Lopez added.

Previous articleNew Screening Approach Said to Help Speed up Identification of Leads for Drug Discovery
Next articleRoche to License Type 2 Diabetes Drug from Ipsen for Euro230 million